CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) New Investor Presentation Shows Value-Added Milestones for Berubicin in 2021
GBM is diagnosed in more than 13,000 people each year in the US, with only a 12–18-month life expectancyPotentially pivotal Phase 2 trial of Berubicin is scheduled to commence around the end of Q1 2021The company is continuing its pre-clinical work on WP1244 during 2021 and 2022CNS Pharmaceuticals participated in two virtual conferences during March, spreading awareness about Berubicin and the GBM indicator CNS Pharmaceuticals…